Lencya

Ulipristal acetate, the active ingredient in Lencya, is a selective progesterone receptor modulator presented as an oral tablet for systemic use. It is employed to prevent pregnancy after unprotected intercourse and to manage symptomatic uterine fibroids in adult women.

GNH USA supplies Lencya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution.

Lencya (ulipristal acetate) acts as a selective progesterone receptor modulator and is used in reproductive health and gynecologic conditions.

- Emergency contraception: when administered up to five days after unprotected sexual intercourse, it can inhibit or delay ovulation, thereby reducing the risk of pregnancy in women of reproductive age. - Uterine fibroids: in premenopausal women, it can be used to shrink fibroid tissue and alleviate heavy menstrual bleeding, offering a non‑surgical therapeutic option.

Ulipristal acetate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Abdominal pain - Fatigue - Menstrual irregularities

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Liver enzyme elevation or hepatitis - Persistent or worsening abdominal pain suggesting possible uterine complications

When prescribing Lencya, clinicians should consider several precautionary measures to ensure safe use.

- Pregnancy contraindication: avoid use in confirmed or suspected pregnancy. - Liver disease: assess hepatic function before initiating therapy. - Concomitant hormonal contraception: do not rely on Lencya as a regular contraceptive method. - Known hypersensitivity: discontinue if allergic reactions occur. - Drug interactions: review concomitant medications that may affect efficacy. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Ulipristal acetate can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, St John’s wort): may markedly reduce drug levels. - Combined hormonal contraceptives: may decrease efficacy of both agents.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin, phenobarbital): may modestly lower plasma concentrations. - Antifungal agents (e.g., ketoconazole, itraconazole): may increase exposure, requiring monitoring. - Antiretrovirals (e.g., efavirenz): potential interaction affecting metabolism.